<p><a href="http://bit.ly/2Fi00oo" target="_blank" rel= "noopener">Wize Pharma</a> (OTCQB: WIZPD) is a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including Dry Eye Syndrome. Wize Pharma has inlicensed certain rights to purchase, market, sell and distribute a formula known as LO2A, a drug developed for the treatment of Dry Eye Syndrome, and other ophthalmological illnesses, including Sjorgen's Syndrome and Conjunctivochalasis.</p>

Wize Pharma (OTCQB: WIZPD) is a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including Dry Eye Syndrome. Wize Pharma has inlicensed certain rights to purchase, market, sell and distribute a formula known as LO2A, a drug developed for the treatment of Dry Eye Syndrome, and other ophthalmological illnesses, including Sjorgen's Syndrome and Conjunctivochalasis.

<p><a href="http://bit.ly/2Fi00oo" rel="noopener noreferrer">Wize Pharma</a> (OTCQB: WIZPD) is a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including Dry Eye Syndrome. Wize Pharma has inlicensed certain rights to purchase, market, sell and distribute a formula known as LO2A, a drug developed for the treatment of Dry Eye Syndrome, and other ophthalmological illnesses, including Sjorgen's Syndrome and Conjunctivochalasis.</p>

Wize Pharma, Inc.

OTC Markets presents our podcast series on the OTCQB Market, where we interview the entrepreneurs behind the companies that trade on the venture market.

Share Wize Pharma, Inc.

Sign up to save your podcasts

Wize Pharma, Inc.

Wize Pharma, Inc.